AACR and Bayer Offering Research Grants

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Association for Cancer Research and Bayer announced the 2016 AACR-Bayer Innovation and Discovery Grants program for meritorious projects that examine novel targets and biomarkers in oncology research.

The grants will promote the Bayer Grants4Targets initiative, originally introduced in 2009, to provide new treatment options for cancers with high unmet medical need, encourage innovation and translation of ideas from basic research into novel drugs, and foster collaborations between academic groups and the pharmaceutical industry.

The research proposed for funding should examine novel therapeutic targets focusing on the following oncology research areas: inhibition of cell proliferation; survival signaling; transcription and chromatin modulation; cell cycle regulation; tumor metabolism; hypoxia; immunotherapy; and antibody-drug conjugates.

Each grant will provide $10,000 to $25,000 over a period of one year, with the grant term to begin July 1. All the recipients will be offered the opportunity to work with a Bayer mentor who will provide guidance, expertise, and/or tools to accelerate the translation of their scientific idea.

To complete an application, please visit http://myaacr.aacr.org. Applications must be submitted by Jan. 18. Additional inquiries may be directed to Shaun Fitzpatrick at grants@aacr.org.

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login